(01) ABOUT
We identify, in-license, and co-develop programs that target the biological drivers of aging — cellular energy decline, chronic inflammation, and neurodegeneration — using vaccine, small-molecule, and peptide modalities.
Our mission is clear: to extend healthy human lifespan by turning credible longevity science into validated human data.
Our team combines decades of experience in translational medicine, regulatory strategy, and clinical execution under Australia’s CTN/CTX frameworks, enabling sponsors to generate decisive early human data rapidly and cost-effectively.
We partner with academic inventors, biotech founders, and global R&D organizations to design high-quality, biomarker-rich studies that stand up to FDA and EMA scrutiny.
Headquartered in Australia with operations across the ANZ clinical ecosystem, ARVAX operates as an independent translational platform — bridging scientific discovery and regulatory-grade clinical evidence.
Alexander Grinberg
Director of Research and Development at Arvax
Director of Research and Development at Arvax
"At Arvax, we consistently seek founders and researchers developing programs capable of truly transforming how we age. We don’t chase hype; instead, we prioritize rigorous science with a credible mechanism, measurable biomarkers, and a clear path to human validation. If your project targets a biological hallmark of aging and is ready for translation, I encourage you to contact us. We regularly review new opportunities, and when the science aligns with our framework, we act swiftly to build partnerships that turn research into real-world human data." - Alex Grinberg
Platform Expertise
ARVAX combines in-house regulatory, CMC, and clinical operations under one integrated system—the ARVAX Operating System—covering sourcing, evaluation, structure, translation, and scale. This reduces friction between science and execution.
04
Biomarker-Driven Design
Every program we advance integrates a translational biomarker plan—linking mechanism, pharmacodynamics, and clinical endpoints. This ensures each study delivers decision-making data for next-stage development or partnering.
03
Longevity Focus
Unlike generalist CROs or incubators, ARVAX specializes exclusively in longevity and age-related therapeutics—positioning us as the first ANZ platform dedicated to extending healthspan through translational human evidence.
05
Capital Efficiency
Eligible programs benefit from Australia’s 43.5% refundable R&D tax offset and New Zealand’s 15% R&D credit, allowing investors and licensors to advance assets at a fraction of U.S. or EU costs—without compromising quality or compliance.
02
Our Competitive Advantages
Operating under Australia and New Zealand’s CTN/CTX regulatory pathways, ARVAX initiates first-in-human trials in weeks—not months. Our proximity to world-class Phase 1 units and ethics committees enables agile study activation with globally credible data.
01
(02) Our Competitive Advantages
MENU
CONTACTS
Legal Disclaimer
The information provided on this website is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment product. Nothing contained on this site should be interpreted as investment, legal, tax, or other professional advice, and visitors should not rely solely on the information presented herein for making investment or other decisions.
Investments in early-stage biotechnology, vaccines, and preventive medicine companies involve a high degree of risk, including the potential loss of invested capital. Past performance is not indicative of future results, and there can be no assurance that any investment strategy will achieve its objectives.
Any references to portfolio companies, strategic partners, or case studies are provided solely for illustrative purposes and should not be construed as a guarantee of future investment opportunities or performance. Forward-looking statements, projections, or expectations expressed on this site are inherently uncertain and subject to change without notice.
Access to certain investment opportunities is restricted to qualified or accredited investors as defined under applicable securities laws. Visitors should consult with their own legal, financial, and tax advisors before making any investment decisions.
By using this website, you acknowledge and agree that Arvax shall not be liable for any losses or damages arising from reliance on the information contained herein.
This website and its contents are governed by and construed in accordance with the laws of the United Arab Emirates (UAE). Any disputes arising out of or related to the use of this website shall be subject to the exclusive jurisdiction of the courts of the United Arab Emirates.
The information provided on this website is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment product. Nothing contained on this site should be interpreted as investment, legal, tax, or other professional advice, and visitors should not rely solely on the information presented herein for making investment or other decisions.
Investments in early-stage biotechnology, vaccines, and preventive medicine companies involve a high degree of risk, including the potential loss of invested capital. Past performance is not indicative of future results, and there can be no assurance that any investment strategy will achieve its objectives.
Any references to portfolio companies, strategic partners, or case studies are provided solely for illustrative purposes and should not be construed as a guarantee of future investment opportunities or performance. Forward-looking statements, projections, or expectations expressed on this site are inherently uncertain and subject to change without notice.
Access to certain investment opportunities is restricted to qualified or accredited investors as defined under applicable securities laws. Visitors should consult with their own legal, financial, and tax advisors before making any investment decisions.
By using this website, you acknowledge and agree that Arvax shall not be liable for any losses or damages arising from reliance on the information contained herein.
This website and its contents are governed by and construed in accordance with the laws of the United Arab Emirates (UAE). Any disputes arising out of or related to the use of this website shall be subject to the exclusive jurisdiction of the courts of the United Arab Emirates.
